PMC:7321036 / 46546-46720
Annnotations
LitCovid-PD-FMA-UBERON
{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T372","span":{"begin":8,"end":13},"obj":"Body_part"}],"attributes":[{"id":"A372","pred":"fma_id","subj":"T372","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"Vero E6 cells treated with the AXL inhibitor gilteritinib (E), the MAPK11/14 inhibitor ralimetinib (F), or the MAPK13 inhibitor MAPK13-IN-1 (G) prior to SARS-CoV-2 infection."}
LitCovid-PD-MONDO
{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T228","span":{"begin":153,"end":161},"obj":"Disease"},{"id":"T229","span":{"begin":164,"end":173},"obj":"Disease"}],"attributes":[{"id":"A228","pred":"mondo_id","subj":"T228","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A229","pred":"mondo_id","subj":"T229","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"Vero E6 cells treated with the AXL inhibitor gilteritinib (E), the MAPK11/14 inhibitor ralimetinib (F), or the MAPK13 inhibitor MAPK13-IN-1 (G) prior to SARS-CoV-2 infection."}
LitCovid-PD-CLO
{"project":"LitCovid-PD-CLO","denotations":[{"id":"T569","span":{"begin":0,"end":13},"obj":"http://purl.obolibrary.org/obo/CLO_0051719"}],"text":"Vero E6 cells treated with the AXL inhibitor gilteritinib (E), the MAPK11/14 inhibitor ralimetinib (F), or the MAPK13 inhibitor MAPK13-IN-1 (G) prior to SARS-CoV-2 infection."}
LitCovid-PD-CHEBI
{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T325","span":{"begin":31,"end":44},"obj":"Chemical"},{"id":"T326","span":{"begin":35,"end":44},"obj":"Chemical"},{"id":"T327","span":{"begin":45,"end":57},"obj":"Chemical"},{"id":"T328","span":{"begin":77,"end":86},"obj":"Chemical"},{"id":"T329","span":{"begin":118,"end":127},"obj":"Chemical"}],"attributes":[{"id":"A325","pred":"chebi_id","subj":"T325","obj":"http://purl.obolibrary.org/obo/CHEBI_62434"},{"id":"A326","pred":"chebi_id","subj":"T326","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A327","pred":"chebi_id","subj":"T327","obj":"http://purl.obolibrary.org/obo/CHEBI_145372"},{"id":"A328","pred":"chebi_id","subj":"T328","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A329","pred":"chebi_id","subj":"T329","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"}],"text":"Vero E6 cells treated with the AXL inhibitor gilteritinib (E), the MAPK11/14 inhibitor ralimetinib (F), or the MAPK13 inhibitor MAPK13-IN-1 (G) prior to SARS-CoV-2 infection."}
LitCovid-PubTator
{"project":"LitCovid-PubTator","denotations":[{"id":"962","span":{"begin":31,"end":34},"obj":"Gene"},{"id":"963","span":{"begin":67,"end":76},"obj":"Gene"},{"id":"964","span":{"begin":111,"end":117},"obj":"Gene"},{"id":"965","span":{"begin":128,"end":134},"obj":"Gene"},{"id":"966","span":{"begin":45,"end":57},"obj":"Chemical"},{"id":"967","span":{"begin":87,"end":98},"obj":"Chemical"},{"id":"968","span":{"begin":153,"end":173},"obj":"Disease"},{"id":"969","span":{"begin":5,"end":7},"obj":"CellLine"}],"attributes":[{"id":"A962","pred":"tao:has_database_id","subj":"962","obj":"Gene:103234725"},{"id":"A963","pred":"tao:has_database_id","subj":"963","obj":"Gene:103223551"},{"id":"A964","pred":"tao:has_database_id","subj":"964","obj":"Gene:103221595"},{"id":"A965","pred":"tao:has_database_id","subj":"965","obj":"Gene:103221595"},{"id":"A966","pred":"tao:has_database_id","subj":"966","obj":"MESH:C000609080"},{"id":"A968","pred":"tao:has_database_id","subj":"968","obj":"MESH:C000657245"},{"id":"A969","pred":"tao:has_database_id","subj":"969","obj":"CVCL:4582"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Vero E6 cells treated with the AXL inhibitor gilteritinib (E), the MAPK11/14 inhibitor ralimetinib (F), or the MAPK13 inhibitor MAPK13-IN-1 (G) prior to SARS-CoV-2 infection."}
LitCovid-sentences
{"project":"LitCovid-sentences","denotations":[{"id":"T311","span":{"begin":0,"end":174},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Vero E6 cells treated with the AXL inhibitor gilteritinib (E), the MAPK11/14 inhibitor ralimetinib (F), or the MAPK13 inhibitor MAPK13-IN-1 (G) prior to SARS-CoV-2 infection."}